FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589334089> ?p ?o ?g. }

• W2589334089 endingPage "1280" @default.
• W2589334089 startingPage "1274" @default.
• W2589334089 abstract "Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorable responses to chemotherapy. However, secondary intragenic (reversion) mutations that restore protein function lead to clinically significant rates of acquired resistance. The goal of this study was to determine whether reversion mutations could be found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in HGSC. Patients and Methods Plasma and tumor samples were obtained from 30 patients with HGSC with either BRCA1 or BRCA2 germline mutation. Two cohorts were ascertained: patients with a malignancy before undergoing primary HGSC debulking surgery (n = 14) or patients at disease recurrence (n = 16). Paired tumor and plasma samples were available for most patients (24 of 30). Targeted amplicon, next-generation sequencing was performed using primers that flanked germline mutations, whose design did not rely on prior knowledge of reversion sequences. Results Five patients were identified with intragenic mutations predicted to restore BRCA1/2 open reading frames, including two patients with multiple independent reversion alleles. Reversion mutations were only detected in tumor samples from patients with recurrent disease (five of 16) and only in cfDNA from patients with a tumor-detected reversion (three of five). Findings from a rapid autopsy of a patient with multiple independent reversions indicated that reversion-allele frequency in metastatic sites is an important determinant of assay sensitivity. Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequency, also affected assay sensitivity. All patients with reversions detected in tumor-derived DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy. Conclusion Reversion mutations can be detected in an unbiased analysis of cfDNA, suggesting clinical utility for predicting chemotherapy response in recurrent HGSC." @default.
• W2589334089 created "2017-03-03" @default.
• W2589334089 creator A5002569295 @default.
• W2589334089 creator A5008629799 @default.
• W2589334089 creator A5025082628 @default.
• W2589334089 creator A5035884493 @default.
• W2589334089 creator A5057552010 @default.
• W2589334089 creator A5090666071 @default.
• W2589334089 date "2017-04-20" @default.
• W2589334089 modified "2023-10-14" @default.
• W2589334089 title "Reversion of <i>BRCA1/2</i> Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer" @default.
• W2589334089 cites W1485941411 @default.
• W2589334089 cites W1550376883 @default.
• W2589334089 cites W1781764024 @default.
• W2589334089 cites W1983466841 @default.
• W2589334089 cites W1999659306 @default.
• W2589334089 cites W2021341670 @default.
• W2589334089 cites W2034655041 @default.
• W2589334089 cites W2089477889 @default.
• W2589334089 cites W2099101325 @default.
• W2589334089 cites W2102209369 @default.
• W2589334089 cites W2108234281 @default.
• W2589334089 cites W2119180969 @default.
• W2589334089 cites W2120869188 @default.
• W2589334089 cites W2131593373 @default.
• W2589334089 cites W2135525536 @default.
• W2589334089 cites W2138601221 @default.
• W2589334089 cites W2155943701 @default.
• W2589334089 cites W2170928115 @default.
• W2589334089 cites W2171972386 @default.
• W2589334089 cites W2402730620 @default.
• W2589334089 doi "https://doi.org/10.1200/jco.2016.70.4627" @default.
• W2589334089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28414925" @default.
• W2589334089 hasPublicationYear "2017" @default.
• W2589334089 type Work @default.
• W2589334089 sameAs 2589334089 @default.
• W2589334089 citedByCount "149" @default.
• W2589334089 countsByYear W25893340892017 @default.
• W2589334089 countsByYear W25893340892018 @default.
• W2589334089 countsByYear W25893340892019 @default.
• W2589334089 countsByYear W25893340892020 @default.
• W2589334089 countsByYear W25893340892021 @default.
• W2589334089 countsByYear W25893340892022 @default.
• W2589334089 countsByYear W25893340892023 @default.
• W2589334089 crossrefType "journal-article" @default.
• W2589334089 hasAuthorship W2589334089A5002569295 @default.
• W2589334089 hasAuthorship W2589334089A5008629799 @default.
• W2589334089 hasAuthorship W2589334089A5025082628 @default.
• W2589334089 hasAuthorship W2589334089A5035884493 @default.
• W2589334089 hasAuthorship W2589334089A5057552010 @default.
• W2589334089 hasAuthorship W2589334089A5090666071 @default.
• W2589334089 hasConcept C104317684 @default.
• W2589334089 hasConcept C109825262 @default.
• W2589334089 hasConcept C121608353 @default.
• W2589334089 hasConcept C126322002 @default.
• W2589334089 hasConcept C127716648 @default.
• W2589334089 hasConcept C13514818 @default.
• W2589334089 hasConcept C143998085 @default.
• W2589334089 hasConcept C150173356 @default.
• W2589334089 hasConcept C2780427987 @default.
• W2589334089 hasConcept C501734568 @default.
• W2589334089 hasConcept C502942594 @default.
• W2589334089 hasConcept C54355233 @default.
• W2589334089 hasConcept C70883133 @default.
• W2589334089 hasConcept C71924100 @default.
• W2589334089 hasConcept C86803240 @default.
• W2589334089 hasConceptScore W2589334089C104317684 @default.
• W2589334089 hasConceptScore W2589334089C109825262 @default.
• W2589334089 hasConceptScore W2589334089C121608353 @default.
• W2589334089 hasConceptScore W2589334089C126322002 @default.
• W2589334089 hasConceptScore W2589334089C127716648 @default.
• W2589334089 hasConceptScore W2589334089C13514818 @default.
• W2589334089 hasConceptScore W2589334089C143998085 @default.
• W2589334089 hasConceptScore W2589334089C150173356 @default.
• W2589334089 hasConceptScore W2589334089C2780427987 @default.
• W2589334089 hasConceptScore W2589334089C501734568 @default.
• W2589334089 hasConceptScore W2589334089C502942594 @default.
• W2589334089 hasConceptScore W2589334089C54355233 @default.
• W2589334089 hasConceptScore W2589334089C70883133 @default.
• W2589334089 hasConceptScore W2589334089C71924100 @default.
• W2589334089 hasConceptScore W2589334089C86803240 @default.
• W2589334089 hasIssue "12" @default.
• W2589334089 hasLocation W25893340891 @default.
• W2589334089 hasLocation W25893340892 @default.
• W2589334089 hasOpenAccess W2589334089 @default.
• W2589334089 hasPrimaryLocation W25893340891 @default.
• W2589334089 hasRelatedWork W2004144597 @default.
• W2589334089 hasRelatedWork W2087473487 @default.
• W2589334089 hasRelatedWork W2239348802 @default.
• W2589334089 hasRelatedWork W2551427875 @default.
• W2589334089 hasRelatedWork W2947815207 @default.
• W2589334089 hasRelatedWork W3092736101 @default.
• W2589334089 hasRelatedWork W3098236227 @default.
• W2589334089 hasRelatedWork W3207690554 @default.
• W2589334089 hasRelatedWork W3210326642 @default.
• W2589334089 hasRelatedWork W4229868982 @default.
• W2589334089 hasVolume "35" @default.
• W2589334089 isParatext "false" @default.

• next